(14851115), A. E. Z., (14851118), F. S. V., (14851121), R. D., (14851124), S. L. B., (14851127), K. K. B., (14851130), H. E., . . . (14851181), A. F. (2025). Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy.
Citazione stile Chigago Style (17a edizione)(14851115), Amr El Zawily, et al. Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy. 2025.
Citatione MLA (9a ed.)(14851115), Amr El Zawily, et al. Supplementary Table S3 from A Multipronged Unbiased Strategy Guides the Development of an Anti-EGFR/EPHA2–Bispecific Antibody for Combination Cancer Therapy. 2025.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.